金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived Accession #:Q8IU57 N-terminal Sequence Analysis:Arg21 Structure:Disulfide-linked homodimer Purity:>95%, by SDS-PAGE under reducing conditions and visualized by silver stain. Predicted Molecular Mass:50.2 kDa (monomer) SDS-PAGE:65-75 kDa,reducing conditions Activity:Measured by its binding ability in a functional ELISA.In a 100 µL reaction mixture containing rhIL-28 R alpha/Fc Chimera at 1 µg/mL and rhIL-28A (R&D Systems, Catalog # 1587-IL) dilutions at 1 - 1000 ng/mL, the concentration of rhIL-28A that produces 50% of the optimal binding response is found to be approximately 40 - 200 ng/mL. Formulation:Lyophilized from a 0.2 µm filtered solution in PBS.See Certificate of Analysis for details. Molecule Information: IL-28 R alpha/IFN-lambda R1 Long Name: Interleukin 28 Receptor alpha Aliases: CRF2-12; IFN-lambda R1; IFNLR1; IL28RA; LICR2 Entrez Gene IDs: 163702 (Human); 242700 (Mouse); 362628 (Rat) Background: IL-28 R alpha IL-28 receptor alpha subunit, also named interferon-lambda R1, is a type I transmembrane glycoprotein that is cytokine receptor family 2 member 12 (CRF2-12). It pairs with the IL-10 receptor beta subunit (IL-10 R beta, CRF2-4) to form the IL-28 R. This receptor interacts with the interferon-like cytokines (type III interferons) IL-28A (IFN-lambda 2), IL-28B (IFN-lambda 3) and IL-29 (IFN-lambda 1). Signaling through IL-28 R alpha results in upregulated expression of MHC class I antigens and anti-viral, anti-proliferative and anti-tumor activity.